Renewing Hemgenix (etranacogene dezaparvovec) Approval with Blue Cross Blue Shield in Pennsylvania: Annual Requirements and Timeline
Answer Box: Renewing Hemgenix Coverage in Pennsylvania
Hemgenix (etranacogene dezaparvovec) is a one-time gene therapy, but Blue Cross Blue Shield plans in Pennsylvania may require annual clinical documentation for outcomes monitoring and related services coverage. Start renewal submissions 60-90 days before your authorization period expires. Submit updated Factor IX levels,